Data cutoff: October 30, 2026, 8:00 p.m. ET (EDT). Latest completed U.S. equity session: Friday, October 30, 2026.
A post-Humira business model faces another quarterly examination
AbbVie's October 30 third-quarter report offered an unusually clear test of how a large pharmaceutical company can replace revenue from a former blockbuster after loss of exclusivity. The question is no longer whether Humira faces biosimilar competition; it does. The more important financial question is whether the next generation of immunology treatments can grow quickly enough to support earnings while investment in new research and acquired assets continues. Friday's results provided new product-level evidence rather than a generic forecast about the pharmaceutical industry.
The company reported global net revenue of $17.404 billion for the quarter ended September 30, 2026, up 10.3% on a reported basis and 10.5% on an operational basis. GAAP diluted earnings per share were $2.37, while adjusted diluted EPS reached $3.82. Those numbers describe different accounting measures. The company explained that the adjusted figure included a $0.11 per-share unfavorable effect from acquired in-process research and development and milestone expense. Investors should not erase acquisition-related costs when judging the economics of replenishing a pipeline.
Where the growth actually came from
AbbVie's immunology portfolio generated $9.165 billion in quarterly revenue, up 16.3% as reported. Skyrizi contributed $5.776 billion, an increase of 22.7%, and Rinvoq added $2.706 billion, up 23.9%. Together these two products delivered approximately $8.482 billion of revenue. That scale matters more than a single growth percentage: it shows the company is not merely promising replacement therapies but already recording substantial sales from them. However, the combined concentration also creates a new dependency on two major franchises.
Humira revenue, by contrast, fell 31.2% to $683 million. Biosimilar competition and changing contracting conditions remain central to the legacy product's decline. The comparison makes AbbVie's transition unusually measurable. Growth from Skyrizi and Rinvoq can more than compensate for losses in Humira, but it does not eliminate future exclusivity and pricing risks for the replacement products. Payers, formulary rules and clinical differentiation matter for the persistence of market share.
Outside immunology, neuroscience produced $3.389 billion of revenue, up 19.4%. The company reported $1.068 billion from Vraylar and $1.080 billion from therapeutic Botox. Ubrelvy and Qulipta together generated $847 million, while Vyalev contributed $286 million. The distinction between therapeutic Botox and cosmetic Botox is financially meaningful: the products belong to different reported business categories and face different demand and reimbursement considerations. Treating all Botox sales as one homogeneous aesthetic product would misstate the revenue mix.
Guidance, acquisition spending and what is actually comparable
AbbVie increased its full-year 2026 adjusted diluted EPS guidance to $13.95–$13.99 from a prior range of $13.76–$13.96. The new range includes a year-to-date unfavorable impact of $0.69 per share from acquired IPR&D and milestone costs through the third quarter. That caveat is essential. Guidance presented after a business acquisition may include expenses that did not exist in earlier planning scenarios, and comparing point estimates without reading the definitions can create a false impression of the operating change.
The company also confirmed that it had completed its acquisition of Apogee Therapeutics, broadening its immunology research pipeline. Completion of a transaction is an observable corporate event; future drug approvals and commercial success are not. Clinical programs must still meet efficacy and safety standards, regulators must make their own decisions, and competing therapies may be developed in parallel. The company announced a 5.2% dividend increase beginning with a payment in February 2027. That planned distribution demonstrates capital-return priorities but should not be interpreted as a guarantee of future returns.
Why the market may value sales durability over an EPS beat
Biopharmaceutical cash flows often have a distinct pattern: a therapy may enjoy attractive margins while patent and regulatory protection is strong, followed by a potentially steep decline as competitors enter. This creates a need to invest continuously in research, business development and a wider portfolio. AbbVie has handled the Humira transition better than a simple cliff scenario might suggest, judging by the replacement product sales in the quarter. Yet an investor still needs to estimate how long those new sales streams will retain pricing power.
The market debate is therefore about duration, not merely about whether $17.404 billion exceeds a revenue benchmark. A constructive case emphasizes two established growing immunology products, a broader neuroscience business, a raised annual outlook and a commitment to dividends. A cautious case emphasizes product concentration, regulatory uncertainties, reimbursement pressure and the real costs of buying new therapeutic opportunities. Neither case can legitimately declare an experimental medicine approved before a regulator has acted.
Risk assessment and follow-through
The principal risks are trial failures, adverse safety findings, loss of exclusivity, unfavorable formulary placement, price negotiations and unexpected manufacturing costs. New acquisition spending can depress statutory earnings even when adjusted metrics appear stronger. Currency changes also matter because the company reports both reported and operational growth, and those measures should remain separate. Regulatory or reimbursement actions affecting one of the largest franchises can overwhelm a small quarterly earnings surprise. A further concern is assuming that today's growth rates will remain constant as the sales base grows larger.
AbbVie did not establish a definitive date for its next quarterly earnings release in the primary materials reviewed. The next verifiable company-specific evidence will be product-level sales, confirmed clinical trial readouts, regulatory decisions when formally published and any revision to 2026 guidance. Calendar guesses should not be presented as company announcements. For the wider market, the U.S. employment report due November 6 at 8:30 a.m. ET can influence discount rates, but is not a pharmaceutical trial catalyst. Investors should prioritize disclosed events over speculative countdowns.
Conclusion
AbbVie's October 30 report supports the view that Skyrizi and Rinvoq are now the economic center of its immunology business. Their $8.482 billion of combined quarterly sales contrast sharply with Humira's $683 million, while the raised adjusted EPS outlook provides evidence of current earnings confidence. The remaining question is whether portfolio concentration, research costs and pricing pressure will eventually constrain that success. A resilient pharmaceutical valuation depends on repeated clinical and commercial execution, not on one quarter's adjusted earnings figure alone.